- Home
- ALDF vs SGMT Comparison
ALDF vs SGMT Comparison
Compare ALDF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDF
- SGMT
- Stock Information
- Founded
- ALDF 2024
- SGMT 2006
- Country
- ALDF United States
- SGMT United States
- Employees
- ALDF N/A
- SGMT N/A
- Industry
- ALDF
- SGMT
- Sector
- ALDF
- SGMT
- Exchange
- ALDF NYSE
- SGMT Nasdaq
- Market Cap
- ALDF 312.7M
- SGMT 269.2M
- IPO Year
- ALDF 2024
- SGMT 2023
- Fundamental
- Price
- ALDF $10.42
- SGMT $8.69
- Analyst Decision
- ALDF
- SGMT Strong Buy
- Analyst Count
- ALDF 0
- SGMT 6
- Target Price
- ALDF N/A
- SGMT $26.83
- AVG Volume (30 Days)
- ALDF 55.7K
- SGMT 794.8K
- Earning Date
- ALDF 01-01-0001
- SGMT 08-13-2025
- Dividend Yield
- ALDF N/A
- SGMT N/A
- EPS Growth
- ALDF N/A
- SGMT N/A
- EPS
- ALDF N/A
- SGMT N/A
- Revenue
- ALDF N/A
- SGMT N/A
- Revenue This Year
- ALDF N/A
- SGMT N/A
- Revenue Next Year
- ALDF N/A
- SGMT N/A
- P/E Ratio
- ALDF $100.03
- SGMT N/A
- Revenue Growth
- ALDF N/A
- SGMT N/A
- 52 Week Low
- ALDF $9.90
- SGMT $1.73
- 52 Week High
- ALDF $10.69
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- ALDF N/A
- SGMT 51.91
- Support Level
- ALDF N/A
- SGMT $8.74
- Resistance Level
- ALDF N/A
- SGMT $11.41
- Average True Range (ATR)
- ALDF 0.00
- SGMT 0.84
- MACD
- ALDF 0.00
- SGMT -0.21
- Stochastic Oscillator
- ALDF 0.00
- SGMT 18.19
About ALDF ALDEL FINL II INC
Aldel Financial II Inc is a Shell Company with various businesses.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.